These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21076713)

  • 21. Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.
    Barrios V; Escobar C; Zamorano JL
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1597-612. PubMed ID: 24215190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
    Park S; Kang HJ; Rim SJ; Ha JW; Oh BH; Chung N; Cho SY
    Clin Ther; 2005 Jul; 27(7):1074-82. PubMed ID: 16154486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet)].
    Yamazaki H; Fujino H; Kanazawa M; Tamaki T; Sato F; Suzuki M; Kitahara M
    Nihon Yakurigaku Zasshi; 2004 May; 123(5):349-62. PubMed ID: 15118259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia.
    Zhao J; Yan HM; Li Y; Wang J; Han L; Wang ZH; Tang MX; Zhang W; Zhang Y; Zhong M
    J Zhejiang Univ Sci B; 2015 May; 16(5):380-7. PubMed ID: 25990055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
    Kumai T; Oonuma S; Matsumoto N; Takeba Y; Taniguchi R; Kamio K; Miyazu O; Koitabashi Y; Sekine S; Tadokoro M; Kobayashi S
    Life Sci; 2004 Mar; 74(17):2129-42. PubMed ID: 14969717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endothelial Nitric Oxide Synthase-Independent Pleiotropic Effects of Pitavastatin Against Atherogenesis and Limb Ischemia in Mice.
    Mitsuhashi T; Uemoto R; Ishikawa K; Yoshida S; Ikeda Y; Yagi S; Matsumoto T; Akaike M; Aihara KI
    J Atheroscler Thromb; 2018 Jan; 25(1):65-80. PubMed ID: 28592707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The efficacy and safety of pitavastatin].
    Sansoy V
    Turk Kardiyol Dern Ars; 2017 Apr; 45(Suppl 3):1-4. PubMed ID: 28952470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pleiotropic effects of pitavastatin.
    Davignon J
    Br J Clin Pharmacol; 2012 Apr; 73(4):518-35. PubMed ID: 22053916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin.
    Catapano AL
    Curr Vasc Pharmacol; 2012 Mar; 10(2):257-67. PubMed ID: 22022768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pitavastatin decreases the expression of endothelial lipase both in vitro and in vivo.
    Kojima Y; Ishida T; Sun L; Yasuda T; Toh R; Rikitake Y; Fukuda A; Kume N; Koshiyama H; Taniguchi A; Hirata K
    Cardiovasc Res; 2010 Jul; 87(2):385-93. PubMed ID: 20045866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
    Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
    Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia.
    Baker WL; Datta R
    Adv Ther; 2011 Jan; 28(1):13-27. PubMed ID: 21170619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The long-term effects of pitavastatin on blood lipids and platelet activation markers in stroke patients: impact of the homocysteine level.
    Sugimoto H; Konno S; Nomoto N; Nakazora H; Murata M; Kitazono H; Imamura T; Inoue M; Sasaki M; Fuse A; Hagiwara W; Kobayashi M; Fujioka T
    PLoS One; 2014; 9(11):e113766. PubMed ID: 25409188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison.
    Saito Y; Yamada N; Teramoto T; Itakura H; Hata Y; Nakaya N; Mabuchi H; Tushima M; Sasaki J; Goto Y; Ogawa N
    Arzneimittelforschung; 2002; 52(4):251-5. PubMed ID: 12040967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.
    Sadowitz B; Maier KG; Gahtan V
    Vasc Endovascular Surg; 2010 May; 44(4):241-51. PubMed ID: 20403949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of pitavastatin on HDL-cholesterol].
    Tokgözoğlu L
    Turk Kardiyol Dern Ars; 2017 Apr; 45(Suppl 3):5-7. PubMed ID: 28952471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
    Cho Y; Choe E; Lee YH; Seo JW; Choi Y; Yun Y; Wang HJ; Ahn CW; Cha BS; Lee HC; Kang ES
    Metabolism; 2015 Apr; 64(4):482-8. PubMed ID: 25312577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage).
    Han KH; Rha SW; Kang HJ; Bae JW; Choi BJ; Choi SY; Gwon HC; Bae JH; Hong BK; Choi DH; Han KR
    J Clin Lipidol; 2012; 6(4):340-51. PubMed ID: 22836071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor.
    Fukutomi T; Takeda Y; Suzuki S; Ito T; Joh T; Itoh M
    Int J Cardiol; 2010 Jun; 141(3):320-2. PubMed ID: 19138801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.